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doi:10.101The Release of Soluble Factors Contributing to
Endothelial Activation and Damage after
Hematopoietic Stem Cell Transplantation Is Not
Limited to the Allogeneic Setting and Involves Several
Pathogenic Mechanisms
Marta Palomo,1 Maribel Diaz-Ricart,1 Carla Carbo,1 Montserrat Rovira,2
Francesc Fernandez-Aviles,2 Gines Escolar,1 Gu¨nther Eissner,3 Ernst Holler,4 Enric Carreras2This study evaluated the relative impact of the intensity of the conditioning regimen and the alloreactivity in
the endothelial dysfunction occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It
involved a comparative analysis of the effect of incubating human umbilical vein endothelial cells (ECs) with
serum samples from patients receiving autologous HSCT (auto-HSCT) or unrelated donor allo-HSCT. In
both groups, blood samples were collected through a central line before conditioning (Pre), before transplan-
tation (day 0), and at days 7, 14, and 21 after transplantation. Changes in the expression of EC receptors and
adhesion proteins, adhesion of leukocytes and platelets under flow, and signaling pathways were analyzed.
Endothelial activation and damage were observed in both groups, but with differing patterns. All markers
of endothelial dysfunction demonstrated a progressive increase from day Pre to day 14 in the auto-HSCT
group and exhibited 2 peaks of maximal expression (at days 0 and 21) in the allo-HSCT group. Both treat-
ments induced a proinflammatory state (ie, expression of adhesion receptors, leukocyte adhesion, and p38
MAPK activation) and cell proliferation (ie, morphology and activation of ErK42/44). Prothrombotic changes
(ie, von Willebrand factor expression and platelet adhesion) predominated after allo-HSCT, and a proapop-
totic tendency (ie, activation of SAPK/JNK) was seen only in this group. These findings indicate that endo-
thelial activation and damage after HSCT also occur in the autologous setting and affect macrovascular
ECs. After the initial damage induced by the conditioning regimen, other factors, such as granulocyte col-
ony-stimulating factor (G-CSF) toxicity, engraftment, and alloreactivity, may contribute to the endothelial
damage seen during HSCT. Further studies are needed to explore the association between this endothelial
damage and the vascular complications associated with HSCT.
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Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is a well-established treatment for several
hematologic malignancies and other nonmalignant
disorders [1]. Unfortunately, however, allo-HSCT is
associated with several early and late life-threatening
complications produced by the toxicity of the condi-
tioning regimen and by alloimmune reactions [2,3].
Several clinical and preclinical studies have suggested
that injury to the vascular endothelium may contribute
to the initiation and progression of certain early com-
plications after HSCT [4]. The most important of
these complications include veno-occlusive disease
(VOD) of the liver, capillary leak syndrome, throm-
botic microangiopathy, diffuse alveolar hemorrhage,537
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versus-host disease a (aGVHD), all of which carry
significant morbidity and mortality [3,5,6].
Because all of these complications are common in
recipients of allo-HSCT, immune reactions are likely
crucial for their development. The most common
complication in autologous HSCT (auto-HSCT) is
the engraftment syndrome (ES) that develops at the
time of neutrophil engraftment, likely related to endo-
thelial injury [7].
Endothelial cells (ECs) can be injured during allo-
HSCT, first by the chemoradiotherapy included in the
conditioning regimen and by the cytokines produced
by the injured tissues. Later endothelial damage can
result from the translocation of bacterial endotoxins
through the damaged gastrointestinal tract and by
the calcineurin inhibitors used for GVHD prophylaxis
[8,9]. Finally, the vascular endothelium is a target for
allogeneic reactions, probably because it is the initial
allogeneic barrier separating engrafted donor-derived
immune cells from the recipient tissues [6,10,11].
All of these cellular and soluble effectors can induce
localized or diffuse proinflammatory, procoagulant,
and proapoptotic changes in ECs that result in extrav-
asation of fluid out of the vascular space, recruitment
and transmigration of leukocytes, adhesion and aggre-
gation of platelets, activation of procoagulation factors,
and, sometimes, microthrombosis. The inflammatory
component predominates in capillary leak syndrome,
ES, diffuse alveolar hemorrhage, idiopathic pneumo-
nia syndrome, and GVHD, whereas the thrombotic
component is more relevant in VOD of the liver and
thrombotic microangiopathy.
EC damage during HSCT can be evaluated
through the quantification of several soluble markers,
including plasma thrombomodulin, von Willebrand
factor (vWF), and adhesion molecules [12-16]. Unfor-
tunately, all of these biological makers are unspecific
and are seriously hampered by numerous host factors.
Recently, endothelial damage has been evaluated by
quantifying circulating ECs (CECs) and endothelial
microparticles [17,18]. EC cultures offer a unique op-
portunity to evaluate endothelial dysfunction and
damage [19,20]. This approach allows investigators
to reproduce different clinical situations, investigate
the pathophysiologic mechanisms of these complica-
tions, and evaluate different strategies for reducing
endothelial toxicity.
The aim of the present study was to analyze and
compare the endothelial dysfunction caused by serum
from a subgroup of patients at high risk for early com-
plications (ie, recipients of unrelated donor HSCT
conditioned with cyclophosphamide and total body ir-
radiation [Cy1TBI]) with another subgroup that usu-
ally does not develop these complications—recipients
of auto-HSCT conditioned with the BEAM regimen
(ie, BCNU 300 mg/m2 on day27; etoposide 1600mg/m2 on days26,25,24, and23; cytosine arabino-
side 800 mg/m2 on days26,25,24, and23; and mel-
phalan (Mel) 140 mg/m2 on day22). Both the
proinflammatory and prothrombotic effects of the pa-
tient sera on human umbilical vein ECs (HUVECs)
in culture were explored by analyzing the expression
of diverse adhesion molecules, leukocyte adhesion on
EC monolayers, changes in composition and reactivity
of the extracellular matrix (ECM) generated, and the
potential signaling pathways involved. We found that
endothelial injury after HSCT was not limited to mi-
crovascular ECs. All markers of endothelial damage,
excluding activation of the apoptosis pathways, were
increased after both allo-HSCT and auto-HSCT, al-
though with differing kinetic profiles, suggesting possi-
bly different pathogenic mechanisms.PATIENTS AND METHODS
Experimental Design
ECs were obtained from human umbilical veins
and cultured with specific growth medium supple-
mented with pooled sera from healthy donors. Conflu-
ent EC monolayers were exposed to growth media
containing 20% of pooled sera obtained from patients
undergoing auto-HSCT (auto group) or allo-HSCT
(allo group) at different times before and after trans-
plantation.
Changes in the following were assessed: (1) endo-
thelial morphology; (2) expression of endothelial adhe-
sion receptors, such as E-selectin, vascular cell
adhesion molecule 1 (VCAM-1), and intercellular ad-
hesion molecule 1 (ICAM-1); (3) expression of adhe-
sion proteins from ECM, such as von Willebrand
factor (vWF) and tissue factor (TF); (4) adhesion of
leukocytes and platelets on EC monolayers and the
ECM generated by these cells, respectively, under
flow conditions; and (5) intracellular signal transduc-
tion through tyrosine phosphorylation of proteins,
specifically p38 mitogen-activated protein kinase
(MAPK), Erk 42/44, and SAPK/JNK.Patients
Consecutive patients undergoing HSCT at the
Hospital Clinic, Barcelona, between January 2006
and January 2007, were included in the study. Patients
undergoing auto-HSCT who received conditioning
with the BEAM regimen and those undergoing unre-
lated allo-HSCT who received conditioning with Cy
1 TBI were selected. Patients who developed sepsis
during the study period were excluded. The auto
group comprised 11 patients (4 females and 7 males;
median age, 57 years [range, 25 to 68 years]) suffering
from either non-Hodgkin lymphoma (NHL; 10 cases)
or Hodgkin disease (HD; 1 case). All patients were
Biol Blood Marrow Transplant 15:537-546, 2009 539Endothelial Activation in HSCTtreated with the BEAM regimen. The allo group com-
prised 12 patients (5 females and 7 males; median age,
36 years [range, 19 to 48 years]) with acute myeloge-
nous leukemia (AML; 6 cases), acute lymphoblastic
leukemia (ALL; 2 cases), myelodysplastic syndrome
(MDS; 2 cases), chronic myelogenous leukemia
(CML; 1 case), or chronic lymphocytic leukemia
(CLL; 1 case). These patients were treated with Cy
(120 mg/kg on days27 and26) and TBI (12 Gy in 4
fractions on days24,23,22, and21). Cyclosporin
(CsA; 1 mg/kg/day from day27 to day21, followed
by 3 mg/kg/day) plus a short course of methotrexate
(MTX; 4 doses) was administered for GVHD prophy-
laxis.
Engraftment (.5  109/L of neutrophils) oc-
curred after 10.7 6 1.1 days (mean 6 standard error
of the mean) in the auto group and 17.5 6 4.4 days
in the group (P\ .001). Three patients in the auto
group developed ES between days 11 and 13, and 2 pa-
tients in the allo group developed aGVHD grade II, at
days 14 and 18.
Informed consent for blood utilization was ob-
tained from all patients. The study was approved by
the Hospital Clinic’s Ethical Committee and was car-
ried out in accordance with the principles of the
Declaration of Helsinki.
Sample Collection
Blood samples were obtained at different time
points of the study: Pre (before the start of the condi-
tioning regimen), day 0 (immediately before HSCT),
and days 7, 14, and 21 after HSCT. All samples were
obtained through a central line, to avoid sample con-
tamination with EC. Serum samples were obtained
by centrifuging blood at 3000  g for 15 minutes.
These samples were stored at 220C until the day of
the analysis, at which time pools of sera for the
different time points were prepared.Human Endothelial Cell Culture
HUVECs were isolated from human umbilical
veins as described previously [21]. The cells were
maintained and subcultured at 37C in a 5% CO2 hu-
midified incubator in Medium 199 (GIBCO/BRL Life
Technologies, Paisley, UK), supplemented with 100
U/mL of penicillin, 100 g/mL of streptomycin
(GIBCO/BRL Life Technologies), and 20% pooled
human sera. Cells were used at a second passage.
When required, cells were grown to confluence on
1% gelatin-coated glass coverslips. In some experi-
ments, the composition and reactivity of the ECMs
were evaluated. For this, EC monolayers grown on
glass coverslips were treated with a 3% solution of
ethyleneglycoltetraacetic acid (EGTA) on Hanks’
solution for 1 hour at 37C, to extract the cells and
maintain the ECM on the coverslip.Immunogold Labeling and Silver Enhancement
Glass coverslips coated with ECs incubated with
the sera pool for 4 days and ECMs obtained from cells
incubated under the same conditions for 7 days were
fixed with 4% paraformaldehyde in 0.15 M phos-
phate-buffered saline (PBS; pH 7.4) for 10 minutes
at 4C. The proteins evaluated were VCAM-1,
ICAM-1, and ELAM-1 on ECs and vWF and TF on
ECMs. Fixed coverslips were incubated with mono-
clonal antibodies against VCAM-1 (1/100 dilution;
Chemicon, Temecula, CA), ICAM-1 (1/100 dilution;
Chemicon), E-selectin (1/100 dilution; Southern Bio-
technology, Birmingham, AL), vWF (1/1000 dilution;
Dako, Glostrup, Denmark), and TF (1/1000 dilution;
American Diagnostica, Stamford, CT) for 45 minutes
at room temperature, or with an unspecific IgG
(n5 6). After removing the excess of antibody by wash-
ing 3 times with PBS, coverslips were incubated with
a gold-conjugated goat anti-mouse IgG (1/1000 dilu-
tion; Amersham Pharmacia Biotech, Essex, UK) for 1
hour at room temperature. Finally, the samples were
treated with an intense silver enhancement reagent
(Amersham Pharmacia Biotech) to visualize gold parti-
cles bound to the antigen [22,23]. The density of gold
particles bound was morphometrically analyzed in
a light microscope (Polyvar; Reichert-Jung, Vienna,
Austria) equipped with epipolarizing filters. Images
were captured by a video camera (ProgRes MF;
Jenoptik, Jena, Germany) and transferred to a personal
computer with an automated image analysis system
(SigmaScan; Jandel Scientific, San Rafael, CA) for
the evaluation of the density of gold particles on ECs
and ECMs (expressed as gold particles per mm2).Perfusion Studies
Leukocyte Adhesion on EC Monolayers
Leukocyte adhesion on ECs was explored using
a parallel-plate perfusion chamber [22,24,25]. EC
monolayers, grown for 4 days with medium supple-
mented with sera of patients from both groups, were
perfused with citrated blood at a shear rate of 300 s-1
for 10 minutes. After perfusion, the coverslips were
carefully washed with PBS and stained with May-
Gru¨nwald and Giemsa stains. The coverslips were ex-
amined with a light microscope (magnification 320),
and the number of adherent leukocytes was expressed
as a percentage with respect to the number of ECs
(number of leukocytes per 100 ECs).
Platelet Adhesion on ECMs
Perfusion studies to evaluate platelet adhesion on
ECMs were carried out in a parallel-plate perfusion
chamber at a shear rate of 800 s-1 for 5 minutes
[24,26]. For each perfusion, two coverslips were in-
serted in separate receptacles of a parallel-plate
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of whole blood anticoagulated with citrate (100 mM
sodium citrate, 16 mM citric acid, 18 mM sodium hy-
drogen phosphate, and 130 mM dextrose; final citrate
concentration, 19 mM) from a single healthy donor.
After perfusion, coverslips were rinsed with 0.15 M
PBS, fixed with 0.5% glutaraldehyde in 0.15 M PBS
at 4C for 24 hours, and stained with 0.02% toluidine
blue. The degree of platelet deposition in the perfused
surface was measured in 10 microscopic fields per cov-
erslip (magnification 320), and evaluated en face by
means of an automated method, as described previ-
ously [27]. The surface covered by platelets was
expressed as a percentage with respect to the total
area of the coverslip screened (%SC).
Evaluation of Phosphorylation Kinetics of p38
MAPK, Erk42/44, and SAPK/JNK
To evaluate the effect of patient sera on p38
MAPK, Erk 42/44, and SAPK/JNK, ECs were starved
24 hours before experimentation. Before and after
being exposed to a sera pool (for durations of 30
seconds to 5 minutes), the ECs were lysed with
Laemmli’s buffer (68.5 mM Tris, 2% sodium dodecyl
sulfate, 10% glycerol, 5 mM b-mercaptoethanol, and
0.003% bromophenol blue) containing 2 mM sodium
ortho-vanadate and 0.625 mg/mL N-ethylmaleimide
as inhibitors. Samples were resolved by 8% sodium do-
decyl sulfate–polyacrylamide gel electrophoresis and
transferred onto nitrocellulose membranes (BioRad,
Hercules, CA), which were probed with specific anti-
bodies to phosphorylated proteins: p38 MAPK,
Erk42/44, and SAPK/JNK (Cell Signaling Technol-
ogy, Danvers, MA) [28,29]. The presence of proteins
was confirmed using specific antibodies.
Statistical Analysis
Results are expressed as mean 6 standard error of
the mean (SEM) obtained from replicate experiments
(n 5 6 for each approach). Evaluation of the experi-
ments was always blinded and verified by a secondFigure 1. Cell growth and morphological changes. Light micrographs showin
lected from patients in the auto group at day 14 (B) and from patients in the al
layers. The arrows point out differences in cell morphology and the pres
representative of 6 different experiments.(senior) investigator. Statistical analyses were per-
formed using the Student t-test for paired samples,
and results were considered significant when P\ .05.
The SPSS statistical package (SPSS Inc, Chicago, IL)
was used for all analyses.RESULTS
Cell Growth and Morphological Changes
Exposure of ECs to media supplemented with sera
from patients from either the auto group or the allo
group resulted in alterations in both cell morphology
and growth kinetics. Proliferation was accelerated
in ECs exposed to sera from both groups, which
achieved confluence earlier compared with control
ECs. Moreover, in both experimental situations, the
cells exhibited variable sizes, irregular shapes, abun-
dant vacuoles, and the presence of detritus. These phe-
nomena were more noticeable at day 14 in the auto
group (Figure 1B), whereas in the allo group, they
were detected mainly at days 0 and 21 (Figure 1C).Expression of Adhesion Molecules in EC
Monolayers
Changes in the expression of VCAM-1, ICAM-1,
and E-selectin on the surface of ECs in culture were
explored by immunocytochemistry using gold stain-
ing. In control experiments, VCAM-1 and E-selectin
were not detected, and ICAM-1 expression was 7 6
4.1 pixels/mm2. Increased expression of the 3 adhesion
molecules, especially at gap junctions, was detected in
cells grown in the presence of sera from patients in
both the auto and allo groups (see Figure 2D–F for
VCAM-1 expression).
In the auto group, VCAM-1 expression increased
progressively from day Pre (35 6 14.1 pixels/mm2) to
day 14, the day on which it reached a peak of maximal
expression (896 8.2 pixels/mm2) (P\ .05 vs Pre), after
which it decreased up to day 21 (58.36 10 pixels/mm2)
(Figure 2E). ICAM-1 expression was similar tog EC monlayers grown in the presence of control sera (A) and sera col-
lo group at day 21 (C). The images correspond to semiconfluent mono-
ence of detritus in (B) and (C), respectively. These micrographs are
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Figure 2. Expression of VCAM-1, ICAM-1, and E-selectin on the surface of ECs. Light micrographs (original magnification, 320 for all micrographs)
show ECmonolayers grown in the presence of sera from controls (A and D), from patients in the auto group at day 14 (B and E), and from patients in the
allo group at day 21 (C and F). Micrographs (D), (E), and (F) correspond to images captured with the epi-polarizing filter to visualize VCAM-1 expression
and are representative of 6 different experiments. Bar diagrams represent the density of gold labeling (pixels/mm2; mean6 SEM; n5 6), corresponding to
the expression of the adhesion receptors VCAM-1, ICAM-1, and E-selectin in cells grownwith sera from patients in the auto group (G) and the allo group
(H). *P\.05 versus Pre condition.
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earlier (Figure 2G). Expression of E-selectin was not
as significant as that for the other receptors
(Figure 2G).
In the allo group, changes in the expression of the 3
molecules were more noticeable and appeared earlier,
reaching 2 maximal peaks of expression at day
0 (93.3 6 7 pixels/mm2; P\ .05 vs day Pre) and day
21 (70 6 9.2 pixels/mm2; P \ .05 vs day Pre)
(Figure 2H). Because the most notable changes were
always detected at day 14 in the auto group and at
day 21 in the allo group, these figures consistently
show images corresponding to the data obtained at
these time points.Leukocyte Adhesion on ECs Exposed to Blood
under Flow Conditions
Adhesion of leucocytes to EC monolayers was ex-
plored under flow conditions with citrated blood, us-
ing a parallel-plate perfusion chamber (300 s-1, 10
minutes) (Figure 3). Under the experimental condi-
tions, some degree of leukocyte adhesion on controlEC monolayers was observed (1.5% 6 0.5%; n 5 6)
(Figure 3A). Interestingly, adhesion of leukocytes on
ECs grown in the presence of sera from both groups
of patients paralleled the findings for the expression
of VCAM-1 and ICAM-1 receptors.
On monolayers grown with sera from the auto
group, the percentage of leucocyte adhesion increased
progressively from day Pre to day 14 (Figure 3B), day
on which it reached its maximum value (6.13%6
0.4%; n 5 6; P\ .05 vs Pre condition) (Figure 3D).
In the allo group, the percentage of leukocyte ad-
hesion showed 2 peaks, at day 0 (4.7% >6 0.8%; n 5
6) and day 21 (4.9% 6 0.3%; n 5 6) (Figure 3C).
Both of these values were significantly higher (P \
.05) than those observed at day Pre (2.5% 6 0.5%; n
5 6) (Figure 3E).Platelet Adhesion on ECM under Flow
Conditions
Changes in the reactivity of the ECMs generated
by the ECs grown in the presence of sera from the var-
ious study groups were evaluated by exposing the
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Figure 3. Adhesion of leukocytes on ECs exposed to blood under flow conditions. Light micrographs (original magnification,320 for all micrographs)
showing leukocytes (arrows) adhered to ECMs grown in the presence of control sera (A), sera from patients in the auto group at day 14 (B), and sera
from patients in the allo group at day 21 (C). The bar diagrams represent data corresponding to the adhesion of leucocytes, expressed as a percentage
with respect to the number of ECs (number of leukocytes/100 ECs; mean6 SEM; n5 6) grownwith sera from patients in the auto group (D) and the allo
group (E). The dotted line represents the mean value for control results. *P\.05 versus Pre condition.
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conditions (800 s-1, 5 minutes). In control experi-
ments, the percentage of surface covered by platelets
(%SC) was 20.1% 6 1.3% (n 5 12) (Figure 4A).
After the perfusion of ECMs from ECs grown with
media supplemented with sera from the auto group,
the %SC at day Pre was slightly superior to that found
in control experiments (23.4% 6 1.5% vs 20.1% 6
2.4%; n 5 6; P\ .05). A statistically significant in-
crease was measured only at day 14 (31.5% 6 1.7%;
n 5 6; P\ .05 vs day Pre) (Figure 4B), and the values
returned to control values at day 21 (20.47% 6 2.9%;
n 5 6) (Figure 4D).
The %SC values were significantly higher in the
allo group than in the auto group and in the controls.
In the allo group, the %SC was 26.8%6 0.9% (n5 6)
at day Pre (P\ .05 vs control) and it increased signif-
icantly, to 37%6 1.3% at day 0 and 35.5%6 1.4% at
day 21 (P\ .05 vs day Pre) (Figure 4E).Detection of vWF and TF on ECM
We measured changes in the expression of vWF
and TF in the ECMs of ECs grown in the presence
of the sera under study. The ECMs grown with media
supplemented with sera from the auto group exhibited
increased vWF expression (Figure 5A), with the differ-
ence reaching statistical significance at day 14 with re-
spect to day Pre (53.76 6.2 vs 28.66 8 gold particles/
mm2; n 5 6; P\ .05). In the allo group, the density of
labeling for vWF on ECMs exceeded that in the con-
trol experiments even at day Pre (34.7 6 5.4 vs 30 6
2 gold particles/mm2), with the difference reaching sta-
tistical significance at days 0 and 21 (596 7.3 and 48.16 5.9 gold particles/mm2, respectively; P\ .05 vs day
Pre) (Figure 5B).
TF expression was low in control ECMs and re-
mained unchanged in ECMs from both the auto and
groups.Phosphorylation Kinetics of p38 MAPK, Erk 42/
44, and SAPK/JNK
Phosphorylation of the MAP kinases p38 MAPK,
Erk 42/44, and SAPK/JNK was evaluated using the
same experimental design (n 5 6). Activation of p38
MAPK occurred after day 14 in the auto group and af-
ter day 0, with peaks of intense phosphorylation at days
0 and 21, in the allo group. Rapid phosphorylation (30
seconds) was seen in both the allo and auto groups.
Phosphorylation was heavier in the allo group
(Figure 6A) and lasted for at least 15 minutes.
The phosphorylation kinetics of Erk 42/44 fol-
lowed the same tendency seen for the markers of endo-
thelial dysfunction (Figure 6B). The auto group
demonstrated a progressive activation in the days after
transplantation. In the allo group, Erk 42/44 appeared
to be phosphorylated especially at days 0 and 21. Phos-
phorylation was rapid (within 30 seconds) and
persisted for at least 5 minutes after exposure to the
patient sera.
Phosphorylation of SAPK/JNK was not detected in
ECs exposed to sera from the auto group at any time
point. In the allo group, activation of SAPK/JNK fol-
lowed the same pattern as seen for p38 MAPK and
Erk 42/44, appearing phosphorylated especially at
days 0 and 21. Phosphorylation of SAPK/JNK was
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Figure 4. Platelet adhesion on ECMs generated by ECs. Light micrographs (original magnification, 320 for all) show platelet interaction with ECM
from cells grown in the presence of control sera (A) and sera from patients in the auto group at day 14 (B) and from those in the allo group at day
21 (C). Images are representative of 6 different experiments. Perfusion experiments were performed with citrated blood at 800 s-1 for 5 minutes.
Bar diagrams represent the percentage of surface covered by platelets (%SC) expressed as mean 6 SEM (n 5 6 on the ECM generated by EC grown
with sera from patients in the auto group (D) and the allo group (E)). The dotted line represents the mean value for control results. *P\.05 versus Pre
condition #P\.05 versus control.
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after exposure to the patient sera (Figure 6A).
The presence of the 3 proteins under study was
confirmed to be homogeneous in all samples evaluated
by incubating the immunoblots with specific anti-
bodies (Figure 6).DISCUSSION
Endothelial damage has been associated with allo-
HSCT, an established method for treating hemato-
logic malignancies and other nonmalignant diseases.
To evaluate the relative impacts of the intensity of the
conditioning regimen and of alloreactivity, we con-
ducted a comparative analysis of the effects of incubat-
ing macrovascular ECs in vitro with sera samples from
patients undergoing auto-HSCT and allo-HSCT. Our
findings indicate that an inflammatory reaction of ECs
occurs in both groups. This reaction is characterized by
increased expression of adhesion receptors on the sur-
face of ECs in culture, with leukocyte adhesion when
cells are exposed to circulating blood, and activation
of p38 MAPK. In addition, we observed a prothrom-
botic effect that was much more pronounced in the
allo group, with ECs producing ECMs enriched with
vWF, with increased platelet adhesion when exposed
to blood under flow conditions. Both the allo and the
auto groups exhibited cell proliferation, as measured
by activation of Erk 42/44. Interestingly, when evalu-
ated by measuring activation of the SAPK/JNK path-
way, apoptosis was seen only the allo group.Using our experimental approach, markers of en-
dothelial dysfunction were increased in macrovascular
EC cultures. These alterations were not limited to the
apoptosis observed by Eissner et al. [30] in HUVECs
receiving ionizing radiation, suggesting silent damage
of the whole endothelium in addition to the microvas-
cular damage responsible for the clinical manifesta-
tions occurred after HSCT. Whether this systemic
macrovascular damage is implicated in the early vascu-
lar events and in the high incidence of cerebral, coro-
nary, and peripheral cardiovascular events seen even
in young persons long after HSCT remains to be
elucidated [31,32].
The endothelial dysfunction observed in both the
allo and auto groups had a different profile in the first
weeks after HSCT. A kinetic analysis of our findings
revealed some degree of endothelial activation even
before the conditioning regimen in both the auto and
allo groups, being more evident in the latter. More-
over, endothelial dysfunction was found in both
groups at the time of transplantation (day 0), to
a much more intense degree in the allo group. Clearly,
this must be attributed to the toxicity of the
conditioning regimen, especially to the use of TBI in
the allo-HSCT setting [30]. It should be noted that
the conditioning used in the auto-HSCT setting,
despite being less intensive than that used in allo-
HSCT, cannot be considered reduced intensity condi-
tioning, (RIC) because it included a higher dose of
etoposide than that included in the classical BEAM
regimen. This fact could explain why some authors
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Figure 5. vWF concentrations on ECMs from EC monolayers evalu-
ated by immunocytochemistry using gold staining. The bar diagrams rep-
resent the expression of vWF (gold particles/mm2) on ECMs generated
by EC monolayers grown in the presence of sera from patients in the
auto group (A) and the allo group (B). Values are mean 6 SEM
(n5 6). *P\.05. The dotted line represents the mean value for control
results.
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with true RIC regimens found no endothelial dysfunc-
tion [14].
After transplantation, the degree of endothelial
damage exhibited a different profile in the allo and
auto groups. In the auto group, markers of endothelial
damage increased progressively up to day 14 and de-
creased thereafter. The values found on day 7 cannot
be attributed to the use of granulocyte colony-stimu-
lating factor (G-CSF), a well-known proinflammatory
agent [33], because G-CSF was given to all of our pa-
tients on day 7, just after blood samples were drawn for
this study. Because the time to engraftment (. 5 
109/L neutrophils) was 10.7 6 1.1 days in the auto
group, it is plausible that the progressive endothelial
dysfunction observed in this setting may be related to
changes associated with the engraftment process. Evi-
dently, both engraftment and G-CSF could play roles
in the damage seen on day 14. The extreme dysfunc-
tion observed at that time also could explain why 3 of
the 11 patients in the auto group developed ES be-
tween days 7 and 14.
We found a completely different pattern in the allo
group. Markers of endothelial dysfunction tended to
decrease at days 7 and 14. This tendency practically
excludes the possibility of a role of CsA, which
was administered at high doses starting at day21.Interestingly, this same evolutive pattern was reported
by Woywodt et al. [18] when quantifying circulating
ECs in a subgroup of patients receiving TBI. Because
these patients had not received G-CSF, the second
peak occurring at day 21 could be attributed only to
the first alloreactivity phenomenon or, as in the autol-
ogous setting, to the engraftment of donor cells occur-
ring after 17.56 4.4 days in this group. These 2 peaks
of endothelial dysfunction also were noted by Salat
et al. [15] when analyzing vWF levels in patients un-
dergoing allo-HSCT with or without GVHD, sug-
gesting a possible mechanism linked to engraftment.
A similar conclusion was reached by Ganster et al.
[34] in a study of apoptosis in patients undergoing
allo-HSCT. More studies of endothelial function on
day 28 after HSCT are needed to elucidate the actual
impact of each of these factors.
Our morphological findings indicate changes in
growth and morphology in ECs exposed to sera from
recipients of auto-HSCT and allo-HSCT. In both
groups, these ECs reached confluency more rapidly
than control cells, with activation of Erk 42/44, al-
though the timing was different in the 2 groups. Inter-
estingly, despite the accelerated proliferation, these
cells readily detached when monolayers were exposed
to circulating anticoagulated blood. This observation
correlates with previous reports of increased numbers
of circulating ECs [15,18]. In addition, the possible ap-
optosis (as evidenced by increased presence of cell de-
tritus in the growth media) was confirmed by
activation of SAPK/JNK in the allo group, but not in
the auto group.
Our findings indicate that the HSCT environment
is proinflammatory. Although this observation has
been reported for allo-HSCT [4,15], little direct evi-
dence of it has been found in auto-HSCT. In the pres-
ent study, the expression of VCAM-1 and ICAM-1 as
markers of endothelial damage followed the kinetics
seen for both types of HSCT, with excellent correla-
tion with the interaction of circulating leukocytes on
EC monolayers exposed to flowing blood. ECs do
not have storage forms of endothelial adhesion recep-
tors [15,35] and their expression depends largely on
new mRNA synthesis. In fact, we found that the in-
creased VCAM-1 and ICAM-1 expression was closely
correlated with p38 MAPK phosphorylation.
Our findings indicate that along with a proinflam-
matory effect, allo-HSCT leads to a higher and more
persistent prothrombotic state. The ECMs generated
by cells grown in the presence of sera from patients
in both groups were more reactive to platelets com-
pared with control ECMs when exposed to circulating
blood. This reactivity was much more notable in
ECMs from the allo group and was significant only
at day 14 in the auto group, in accordance with the
changes seen in vWF expression. These findings are
in agreement with the higher incidence of VOD and
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Figure 6. Phosphorylation kinetics of p38 MAPK, SAPK/JNK, and Erk 42/44. (A) Phosphorylation kinetics of p38MAPK and SAPK/JNK in cells exposed
to control sera and sera from patients in the auto group at day 14 and from patients in the allo group at day 21, for 0 seconds, 30 seconds, and 5 minutes.
(B) Phosphorylation kinetics of Erk42/44 after 30-second exposure of cells to the sera samples collected at the different time points, as indicated. Blots
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HSCT recipients [5,15].
The absence of SAPK/JNK pathway activation in
the auto group likely explains the lower incidence
and severity of the endothelial-related complications
in this group. The findings in the allo group on day
0 can be explained by a potentially proapoptotic effect
of the sera of patients receiving TBI, as has been ob-
served in vitro previously [15,30]. The proapoptotic
status observed in the second peak of endothelial
dysfunction can be attributed solely to alloreactivity,
because it was not observed in the auto group.
In conclusion, our findings provide insight into the
endothelial damage that occurs after HSCT. Our
methodology allows us to reproduce different clinical
situations and to evaluate various strategies aimed at
reducing endothelial toxicity and early (and perhaps
also late) complications of HSCT.ACKNOWLEDGMENTS
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